Free Trial

CRISPR Therapeutics (CRSP) Stock Forecast & Price Target

$56.81
+1.25 (+2.25%)
(As of 07/11/2024 ET)

CRISPR Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$75.71
33.28% Upside
High Forecast$112.00
Average Forecast$75.71
Low Forecast$30.00
TypeCurrent Forecast
7/13/23 to 7/12/24
1 Month Ago
6/13/23 to 6/12/24
3 Months Ago
4/14/23 to 4/13/24
1 Year Ago
7/13/22 to 7/13/23
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
7 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
Hold
8 Hold rating(s)
7 Hold rating(s)
6 Hold rating(s)
6 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$75.71$73.46$74.75$71.24
Forecasted Upside33.28% Upside16.15% Upside9.69% Upside35.01% Upside
Get CRISPR Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.

CRSP Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CRSP Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CRISPR Therapeutics Stock vs. The Competition

TypeCRISPR TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.33
2.71
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside33.28% Upside963.83% Upside10.18% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/28/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Chattopadhyay
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral
6/27/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$88.00 ➝ $88.00+55.39%
6/17/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$105.00 ➝ $105.00+71.65%
5/23/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$89.00 ➝ $84.00+50.27%
5/10/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$102.00 ➝ $95.00+85.19%
5/9/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Outperform ➝ Market Outperform$86.00+61.65%
5/9/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$70.00 ➝ $65.00+24.12%
5/9/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$80.00 ➝ $67.00+27.94%
5/9/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral
5/9/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$46.00 ➝ $52.00-2.42%
3/6/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$82.00 ➝ $99.00+22.24%
2/26/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderweight ➝ Underweight$46.00 ➝ $48.00-43.64%
2/22/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSector Perform ➝ Sector Perform$57.00 ➝ $66.00-26.83%
2/22/2024Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$110.00 ➝ $112.00+35.91%
2/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoveragePeer Perform
12/11/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeMarket Perform ➝ Underperform$30.00-53.52%
12/8/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy
8/8/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$62.00 ➝ $63.00+30.33%
5/30/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Corwin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$75.00+15.99%
5/9/2023VNET Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingReiterates
5/9/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$69.00 ➝ $64.00+14.37%
4/17/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$75.00+38.63%
3/21/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$44.00-1.03%
3/17/2023Bryan, Garnier & Co
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$70.00+54.22%
11/7/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$75.00 ➝ $76.00+48.50%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 07:13 AM ET.

CRSP Forecast - Frequently Asked Questions

What is CRISPR Therapeutics' forecast for 2024?

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for CRISPR Therapeutics is $75.71, with a high forecast of $112.00 and a low forecast of $30.00.

Should I buy or sell CRISPR Therapeutics stock right now?

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last year. There are currently 2 sell ratings, 8 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CRSP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRSP, but not buy additional shares or sell existing shares.

Does CRISPR Therapeutics's stock price have much upside?

According to analysts, CRISPR Therapeutics's stock has a predicted upside of 19.39% based on their 12-month stock forecasts.

What analysts cover CRISPR Therapeutics?

CRISPR Therapeutics has been rated by research analysts at Barclays, Cantor Fitzgerald, Citigroup, Guggenheim, JMP Securities, Needham & Company LLC, Oppenheimer, Piper Sandler, Robert W. Baird, and Wells Fargo & Company in the past 90 days.

Do Wall Street analysts like CRISPR Therapeutics more than its competitors?

Analysts like CRISPR Therapeutics less than other "medical" companies. The consensus rating for CRISPR Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CRSP compares to other companies.


This page (NASDAQ:CRSP) was last updated on 7/12/2024 by MarketBeat.com Staff

From Our Partners